Abstract
To date, there is no approved targeted therapy for treatment-naive patients (pts) with METex14 NSCLC in China. Capmatinib, a selective MET inhibitor (METi), is approved for use in this population in >40 countries worldwide, including the US and EU. We report the efficacy and safety of capmatinib as monotherapy in treatment-naive Chinese pts with MET-mutated, advanced NSCLC.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call